secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001193125-24-217627
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres' SER-155 reduces BSIs 10% vs 42.9% in allo-HSCT Phase 1b; seeks Breakthrough Therapy
--------------------------------------------------------------------------------

- SER-155 cut bloodstream infections to 10% vs 42.9% placebo (p=0.0423) in 34 evaluable patients.
- Antibiotic exposure duration significantly shorter: 9.2 days vs 21.1 days (p=0.0494).
- Febrile neutropenia incidence 65% vs 78.6% (not statistically significant).
- No treatment-related serious adverse events; drug strains engrafted in GI tract.
- Plans to seek FDA Breakthrough Therapy designation and discuss next steps for allo-HSCT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524217627/0001193125-24-217627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524217627/d887152d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-217627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer